药物涂层球囊治疗冠状动脉病变的研究进展

doi:10.20047/j.issn1673-7210.2022.32.12

Abstract
Figure/Table
References (30)
Related Citation (15)

Download: PDF (625 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Drug-coated balloon (DCB), as a new type of coronary intervention, for in-stent restenosis and small vessel disease, DCB alone has been accepted by domestic experts and foreign guidelines as an alternative therapy for drug-eluting stent. In addition, studies have found that DCB also shows corresponding advantages in the treatment of primary macrovascular disease, bifurcation disease, chronic total occlusion disease, and other lesions. This paper introduces the characteristics and mechanism of DCB, analyzes and summarizes the clinical application and advantages of DCB in the lesions of large vessels in situ, bifurcation, acute myocardial infarction, chronic total occlusion, calcification, etc., and provides a new idea for the interventional treatment of DCB in coronary heart disease.

Key words： Drug-coated balloon Drug-Eluting stent Coronary artery disease Percutaneous coronary intervention

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WU Zhihao1 WANG Si1 PENG Yangwei1 XIE Junmin1 JIA Xinwei2

Cite this article:

WU Zhihao1 WANG Si1 PENG Yangwei1 XIE Junmin1 JIA Xinwei2. Research progress of drug-coated balloon in the treatment of coronary artery disease[J]. 中国医药导报, 2022, 19(32): 51-54,58.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2022.32.12 OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I32/51

[1] Grüntzig AR，Senning A，Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis：percutaneous transluminal coronary angioplasty [J]. N Engl J Med，1979，301（2）：61-68.
[2] Kuramitsu S，Sonoda S，Ando K，et al. Drug-eluting stent thrombosis：current and future perspectives [J]. Cardiovasc Interv Ther，2021，36（2）：158-168.
[3] Bavry AA，Kumbhani DJ，Helton TJ，et al. Late thrombosis of drug-eluting stents：a meta-analysis of randomized clinical trials [J]. Am J Med，2006，119（12）：1056-1061.
[4] Alfonso F，Scheller B. State of the art：balloon catheter technologies-drug-coated balloon [J]. EuroIntervention，2017，13（6）：680-695.
[5] Nestelberger T，Kaiser C，Jeger R. Drug-coated balloons in cardiovascular disease：benefits，challenges，and clinical applications [J]. Expert Opin Drug Deliv，2020，17（2）：201- 211.
[6] Palmerini T，Della RD，Benedetto U，et al. Three，six，or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes：an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients [J]. Eur Heart J，2017，38（14）：1034-1043.
[7] Corballis NH，Wickramarachchi U，Vassiliou VS，et al. Duration of dual antiplatelet therapy in elective drug-coated balloon angioplasty [J]. Catheter Cardiovasc Interv，2020，96（5）：1016-1020.
[8] Jeger RV，Eccleshall S，Wan AW，et al. Drug-Coated Balloons for Coronary Artery Disease：Third Report of the International DCB Consensus Group [J]. JACC Cardiovasc Interv，2020，13（12）：1391-1402.
[9] Neumann FJ，Sousa-Uva M，Ahlsson A，et al. 2018 ESC/EACTS Guidelines on myocardial revascularization [J]. Eur Heart J，2019，40（2）：87-165.
[10] 陈韵岱，王建安，刘斌，等.药物涂层球囊临床应用中国专家共识[J].中国介入心脏病学杂志，2016，24（2）：61- 67.
[11] Jackson D，Tong D，Layland J. A review of the coronary applications of the drug coated balloon [J]. Int J Cardiol，2017，226：77-86.
[12] Her AY，Yuan SL，Jun EJ，et al. Drug-coated balloon treatment for nonsmall de-novo coronary artery disease：angiographic and clinical outcomes [J]. Coron Artery Dis，2021， 32（6）：534-540.
[13] Yu X，Wang X，Ji F，et al. A Non-inferiority，Randomized Clinical Trial Comparing Paclitaxel-Coated Balloon Versus New-Generation Drug-Eluting Stents on Angiographic Outcomes for Coronary De Novo Lesions [J]. Cardiovasc Drugs Ther，2022，36（4）：655-664.
[14] Venetsanos D，Lawesson SS，Panayi G，et al. Long-term efficacy of drug coated balloons compared with new generation drug-eluting stents for the treatment of de novo coronary artery lesions [J]. Catheter Cardiovasc Interv，2018，92（5）：E317-E326.
[15] Andreou I，Stone PH，Ikonomidis I，et al. Recurrent ather- osclerosis complications as a mechanism for stent failure [J]. Hellenic J Cardiol，2020，61（1）：9-14.
[16] Lassen JF，Holm NR，Banning A，et al. Percutaneous coronary intervention for coronary bifurcation disease：11th consensus document from the European Bifurcation Club [J]. EuroIntervention，2016，12（1）：38-46.
[17] Worthley S，Hendriks R，Worthley M，et al. Paclitaxel- eluting balloon and everolimus-eluting stent for provisional stenting of coronary bifurcations：12-month results of the multicenter BIOLUX-I study [J]. Cardiovasc Revasc Med，2015，16（7）：413-417.
[18] Berland J，Lefevre T，Brenot P，et al. DANUBIO - a new drug-eluting balloon for the treatment of side branches in bifurcation lesions：six-month angiographic follow-up results of the DEBSIDE trial [J]. EuroIntervention，2015，11（8）：868-876.
[19] Kitani S，Igarashi Y，Tsuchikane E，et al. Efficacy of drug- coated balloon angioplasty after directional coronary atherectomy for coronary bifurcation lesions （DCA/DCB registry） [J]. Catheter Cardiovasc Interv，2021，97（5）：E614- E623.
[20] Alawami M，Sadler M，Kasargod C，et al. Outcomes of patients with ST elevation myocardial infarction in the era of second-generation drug eluting stents； five-year follow- up [J]. N Z Med J，2019，132（1506）：34-41.
[21] Byrne RA，Joner M，Kastrati A. Stent thrombosis and restenosis：what have we learned and where are we going? The Andreas Gruntzig Lecture ESC 2014 [J]. Eur Heart J，2015，36（47）：3320-3331.
[22] Gonzalo N，Barlis P，Serruys PW，et al. Incomplete stent apposition and delayed tissue coverage are more frequent in drug-eluting stents implanted during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction than in drug-eluting stents implanted for stable/unstable angina：insights from optical coherence tomography [J]. JACC Cardiovasc Interv，2009，2（5）：445-452.
[23] Vos NS，Dirksen MT，Vink MA，et al. Safety and feasibility of a PAclitaxel-eluting balloon angioplasty in Primary Percutaneous coronary intervention in Amsterdam （PAPPA）：one-year clinical outcome of a pilot study [J]. EuroIntervention，2014，10（5）：584-590.
[24] Vos NS，Fagel ND，Amoroso G，et al. Paclitaxel-Coated Balloon Angioplasty Versus Drug-Eluting Stent in Acute Myocardial Infarction：The REVELATION Randomized Trial [J]. JACC Cardiovasc Interv，2019，12（17）：1691- 1699.
[25] Niehe SR，Vos NS，Van Der Schaaf RJ，et al. Two-Year Clinical Outcomes of the REVELATION Study：Sustained Safety and Feasibility of Paclitaxel-Coated Balloon Angioplasty Versus Drug-Eluting Stent in Acute Myocardial Infarction [J]. J Invasive Cardiol，2022，34（1）：E39-E42.
[26] Koln PJ，Scheller B，Liew HB，et al. Treatment of chronic total occlusions in native coronary arteries by drug-coated balloons without stenting-A feasibility and safety study [J]. Int J Cardiol，2016，225：262-267.
[27] Mahadevan K，Cosgrove C，Strange JW. Factors Influencing Stent Failure in Chronic Total Occlusion Coronary Intervention [J]. Interv Cardiol，2021，16：e27.
[28] Ai H，Wang X，Suo M，et al. Acute- and Long-term Outcomes of Rotational Atherectomy followed by Cutting Balloon versus Plain Balloon before Drug-Eluting Stent Implantation for Calcified Coronary Lesions [J]. Chin Med J （Engl），2018，131（17）：2025-2031.
[29] Iwasaki Y，Koike J，Ko T，et al. Comparison of drug-eluting stents vs. drug-coated balloon after rotational atherectomy for severely calcified lesions of nonsmall vessels [J]. Heart Vessels，2021，36（2）：189-199.
[30] 刘俊呈，司春婴，王贺，等.药物涂层球囊在支架内再狭窄治疗中的应用进展[J].中国医药导报，2019，16（26）：33-36.